Pre-made Rinucumab benchmark antibody ( Whole mAb, anti-PDGFRB therapeutic antibody, Anti-IMF1/KOGS/IBGC4/JTK12/PDGFR/PENTT/CD140B/PDGFR1/PDGFR-1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-484

Pre-Made Rinucumab biosimilar, Whole mAb, Anti-PDGFRB Antibody: Anti-IMF1/KOGS/IBGC4/JTK12/PDGFR/PENTT/CD140B/PDGFR1/PDGFR-1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-484-1mg 1mg 3090 Inquiry Inquiry

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Rinucumab biosimilar, Whole mAb, Anti-PDGFRB Antibody: Anti-IMF1/KOGS/IBGC4/JTK12/PDGFR/PENTT/CD140B/PDGFR1/PDGFR-1 therapeutic antibody
INN Name Rinucumab
TargetPDGFRB
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesRegeneron Pharmaceuticals
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedWet age-related macular degeneration
Development Techna